You are here: Industry Insights > Mount Sinai

News List

Mount Sinai, Boehringer Ingelheim to Evaluate Nintedanib for Fibrosing ILD Following COVID-19 americanpharmaceuticalreview
December 07, 2020
The Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim announced the first patient has enrolled in a new clinical study to investigate the effect of nintedanib in adult patients having acute lung injury following COVID-19 infection.
Lactiga and Mount Sinai sign pact to advance its patented biologic for COVID-19 treatment expresspharma
October 16, 2020
The collaborative team secured an NIH R01 Emergency Award of $2 million dollars to expand this study.
Study shows anticoagulation therapy beneficial for COVID-19 patients europeanpharmaceuticalreview
August 31, 2020
Researchers have demonstrated that all regimens of anticoagulants were far superior to no anticoagulants in COVID-19 patients.
Mount Sinai, Emergent, and ImmunoTek Form Collaboration contractpharma
July 14, 2020
To develop Emergent’s COVID-19 hyperimmune globulin product candidate with U.S. DoD funding.
Sorrento, Mount Sinai to Develop COVI-Shield Antibody Therapy contractpharma
May 13, 2020
Sorrento Therapeutics Inc. and Mount Sinai Health System have agreed to join forces in the investigation and development of an antibody cocktail (COVI-Shield) to potentially treat COVID-19.
Sorrento and Mount Sinai to develop antibody cocktail against Covid-19 pharmaceutical-technology
May 12, 2020
Sorrento Therapeutics has collaborated with Mount Sinai Health System to develop an antibody cocktail, COVI-SHIELD, for the potential treatment of Covid-19.
Mount Sinai and Harbour BioMed collaborate to advance novel biotherapies to treat cancer and coronavirus COVID-19 pharmaceutical-business-review
March 12, 2020
Mount Sinai Health System and Harbour BioMed (HBM) have entered into a multi-year, multifaceted collaboration to develop novel, fully human antibodies for the treatment and prevention of various diseases including oncology and immunology.